Search

Your search keyword '"Pini, M"' showing total 847 results
Start Over Author "Pini, M"
847 results on '"Pini, M"'

154. Fluid dynamic design and analysis of a highly loaded Centrifugal rotor for mini orc power systems

Author

Vitale, S., Pini, M., Ghidoni, A., and Colonna di Paliano, P.

Abstract

Organic Rankine Cycle (ORC) power systems are a well-established technology for the conversion of thermal energy sources in the small-to-medium power range. In the last few years, efforts have been devoted to the development of mini ORC (mORC) power systems (5- 30 kWe) for waste heat recovery from truck engines, or distributed conversion of concentrated solar radiation. In these high-temperature applications the expander is arguably the most critical component. Due to the high expansion ratio, turbo-expanders are typically preferred. Recently, a multi-stage radial-outflow turbine (ROT) configuration for ORC power systems has been studied. However, even if the authors preliminarily demonstrated that ROT may allow for compact and efficient expanders [1], some research questions are still open. Notably, the key point is the fluid dynamic design of the first stages, which are subject to severe flow conditions (very high flow deflection, low aspect ratio of the blades and with high tip clearance losses). This work thus proposes a novel design methodology for centrifugal cascades, specifically targeted to the first rotor of the mORC centrifugal turbine described in Ref. [1]. Blades are initially designed using a novel in-house Turbomachinery Blade Modeler (BM), then performance is verified by means of 3D CFD simulation on unstructured grids using the solver SU2, recently extended also in-house to treat non ideal compressible fluid flows [2]. Results show that traditional blade design rules for axial cascades are not directly extendable to centrifugal profiles and new design guidelines are needed. Moreover, the 3D performance of the cascade has also been investigated by taking into account tip clearance and secondary loss mechanisms. Finally, an accurate comparison with the mean-line code predictions is provided. As expected, the outcome of the study reveals moderate discrepancy between the CFD results and the mean-line code. This suggests that in case of non-conventional machines a more tight integration of design tools of increasing fidelity may be convenient.

Published
2015

155. RIC vs. MAC followed by allogeneic stem cell transplantation for patients with MDS or secondary AML: A prospective, randomized phase III study of the CMWP of the EBMT (RICMAC-Trial)

Author

Kroger, N., Brand, R., Niederwieser, D., Platzbecker, U., Hubel, K., Weber, T., Robin, M., Stelljes, M., Afanasiev, B., Heim, D., Deliliers, G.L., Onida, F., Dreger, P., Pini, M., Guidi, S., Volin, L., Gramatzki, M., Bethge, W., Poire, X., Kobbe, G., Os, M. van, Iacobelli, S., Witte, T. de, and Chronic Malignancies Working Party

Published
2015

156. Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)

Author

Kroger, N., Iacobelli, S., Franke, G.N., Platzbecker, U., Uddin, R., Hubel, K., Scheid, C., Weber, T., Robin, M., Stelljes, M., Afanasyev, B., Heim, D., Deliliers, G.L., Onida, F., Dreger, P., Pini, M., Guidi, S., Volin, L., Gunther, A., Bethge, W., Poire, X., Kobbe, G., Os, M. van, Brand, R., Witte, T.J. de, Kroger, N., Iacobelli, S., Franke, G.N., Platzbecker, U., Uddin, R., Hubel, K., Scheid, C., Weber, T., Robin, M., Stelljes, M., Afanasyev, B., Heim, D., Deliliers, G.L., Onida, F., Dreger, P., Pini, M., Guidi, S., Volin, L., Gunther, A., Bethge, W., Poire, X., Kobbe, G., Os, M. van, Brand, R., and Witte, T.J. de

Abstract

Item does not contain fulltext, Purpose To compare a reduced-intensity conditioning regimen (RIC) with a myeloablative conditioning regimen (MAC) before allogeneic transplantation in patients with myelodysplastic syndrome (MDS) within a randomized trial. Patients and Methods Within the European Society of Blood and Marrow Transplantation, we conducted a prospective, multicenter, open-label, randomized phase III trial that compared a busulfan-based RIC with MAC in patients with MDS or secondary acute myeloid leukemia. A total of 129 patients were enrolled from 18 centers. Patients were randomly assigned in a 1:1 ratio and were stratified according to donor, age, and blast count. Results Engraftment was comparable between both groups. The CI of acute graft-versus-host disease II to IV was 32.3% after RIC and 37.5% after MAC ( P = .35). The CI of chronic graft-versus-host disease was 61.6% after RIC and 64.7% after MAC ( P = .76). The CI of nonrelapse mortality after 1 year was 17% (95% CI, 8% to 26%) after RIC and 25% (95% CI, 15% to 36%) after MAC ( P = .29). The CI of relapse at 2 years was 17% (95% CI, 8% to 26%) after RIC and 15% (95% CI, 6% to 24%) after MAC ( P = .6), which resulted in a 2-year relapse-free survival and overall survival of 62% (95% CI, 50% to 74%) and 76% (95% CI, 66% to 87%), respectively, after RIC, and 58% (95% CI, 46% to 71%) and 63% (95% CI, 51% to 75%), respectively, after MAC ( P = .58 and P = .08, respectively). Conclusion This prospective, randomized trial of the European Society of Blood and Marrow Transplantation provides evidence that RIC resulted in at least a 2-year relapse-free survival and overall survival similar to MAC in patients with MDS or secondary acute myeloid leukemia.

Published
2017

157. Exploratory assessment of a combined-cycle engine concept for aircraft propulsion

Author

De Servi, C.M. (author), Azzini, L. (author), Pini, M. (author), Colonna, Piero (author), De Servi, C.M. (author), Azzini, L. (author), Pini, M. (author), and Colonna, Piero (author)

Abstract

This preliminary study considers a combined cycle configu­ration for aeroengines, whereby thermal energy from the exhaust of the gas turbine is partly recovered in order to obtain additional mechanical power. The waste heat recovery system is based on a closed thermodynamic bottoming cycle with supercritical car­ bon dioxide (scCO2) as working fluid, allowing to achieve a very high power density. As first step of the investigation a thermo­dynamic cycle analysis of the combined-cycle engine (CCE) is carried out. Results are compared to those of the intercooled­recuperative engine (IRE) configuration for the same operating conditions and calculated under the same modeling assumptions. The estimated nominal SFC of the proposed CCE configuration is approximately 20% lower compared to that of a conventional turbofan, and 6% lower than that of the IRE, if pressure drops in the heat exchangers are neglected. Such large gain justified further analysis, by including the preliminary sizing of main components. Once the sizing of heat exchangers is factored in, the thermodynamic benefit of the CCE is offset by the penalty due to the weight of the additional equip­ment. This is mainly caused by i) the space constraints of the turbofan nacelle, which strongly limit the recoverable thermal power, and ii) the lack of proper het exchanger technology for such a highly unconventional application. These issues, and the many other that need consideration, will be addressed in an upcoming research project encompassing a much wider scope involving new aircraft and propulsion system, Flight Performance and Propulsion

Published
2017

158. Numerical investigation of high pressure condensing flows in supersonic nozzles

Author

Azzini, L. (author), Pini, M. (author), Azzini, L. (author), and Pini, M. (author)

Abstract

High-pressure non-equilibrium condensing flows are investigated in this paper through a quasi-1D Euler model coupled to the method of moments for the physical characterization of the dispersed phase. Two different numerical approaches, namely the so-called (a) the mixture and (b) continuum phase model, are compared in terms of computational efficiency and accuracy. The results are verified against experimental data of high-speed condensing steam measured at high pressure (100.7 bar). The analysis demonstrates that Model (b) markedly outperforms the mixture model in terms of computational cost, while retaining comparable accuracy. However, both models, in their original formulation, lead to considerable deviations in the nucleation onset prediction as well as an overestimation of the average droplet radius. A further investigation is then conducted to figure out the main physical parameters affecting the condensation process, i.e. the surface tension, the growth rate and the nucleation rate. It is eventually inferred that applying proper correction to these three quantities allows to obtain best fit with the experimental data. A final calculation is carried out to show the dependence of these three correcting factors from the thermodynamic conditions of the mixture., Flight Performance and Propulsion

Published
2017
Full Text
View/download PDF

159. SU2: The Open-Source Software for Non-ideal Compressible Flows

Author

Pini, M. (author), Vitale, S. (author), Colonna, Piero (author), Gori, G (author), Guardone, A.M.A. (author), Economon, TD (author), Alonso, J (author), Palacios, F (author), Pini, M. (author), Vitale, S. (author), Colonna, Piero (author), Gori, G (author), Guardone, A.M.A. (author), Economon, TD (author), Alonso, J (author), and Palacios, F (author)

Abstract

The capabilities of the open-source SU2 software suite for the numerical simulation of viscous flows over unstructured grid are extended to non-ideal compressible-fluid dynamics (NICFD). A built-in thermodynamic library is incorporated to account for the non-ideal thermodynamic characteristics of fluid flows evolving in the close proximity of the liquid-vapour saturation curve and critical point. The numerical methods, namely the Approximate Riemann Solvers (ARS), viscous fluxes and boundary conditions are generalised to non-ideal fluid properties. Quantities of interest for turbomachinery cascades, as loss coefficients and flow angles, can be automatically determined and used for design optimization. A variety of test cases are carried out to assess the performance of the solver. At first, numerical methods are verified against analytical solution of reference NICFD test cases, including steady shock reflection and unsteady shock tube. Then, non-ideal gas effects in planar nozzles and past turbine cascades, typically encountered in Organic Rankine Cycle applications, are investigated and debated. The obtained results demonstrate that SU2 is highly suited for the analysis and the automatic design of internal flow devices operating in the non-ideal compressible-fluid regime., Flight Performance and Propulsion

Published
2017
Full Text
View/download PDF

160. Unsteady simulation of quasi-periodic flows in Organic Rankine Cycle cascades using a Harmonic Balance method

Author

Rubino, A. (author), Pini, M. (author), Colonna, Piero (author), Rubino, A. (author), Pini, M. (author), and Colonna, Piero (author)

Abstract

Currently, turbomachinery design optimization methodologies are mainly restricted to steady state approaches, due to the high computational cost associated with time-accurate shape optimization algorithms. However, the possibility to include unsteady effects in turbomachinery optimization can significantly increase the level of accuracy of the design predictions, leading to a more realistic representation of the actual performance and ultimately to a substantial increase in operating efficiency. Unsteady effects are particularly relevant in Organic Rankine Cycle turbines. A trade-off between high-fidelity time-accurate unsteady simulations of the flow solution and computational cost is therefore needed at design level. In this paper, a first application of the harmonic balance method to non-ideal compressible flows is presented. The methodology allows to solve the unsteady flow equations for a set of specified frequencies only, with significant computational time savings. An algorithm is proposed for non uniform time sampling in order to resolve frequencies that do not need to be integral multiple of one fundamental harmonic. This enables the solution of quasi-periodically forced non-linear flow problems, in combination with complex fluid models based on accurate equations of state. The method is applied to the unsteady analysis of a supersonic Organic Rankine Cycle stator with quasi-periodic inlet operating conditions, showing about one order magnitude lower computational cost compared to time-accurate simulations., Flight Performance and Propulsion

Published
2017
Full Text
View/download PDF

161. Fluid-dynamic design and characterization of a mini-ORC turbine for laboratory experiments

Author

Pini, M. (author), de Servi, C.M. (author), Burigana, M. (author), Bahamonde, Juan S. (author), Rubino, A. (author), Vitale, S. (author), Colonna, Piero (author), Pini, M. (author), de Servi, C.M. (author), Burigana, M. (author), Bahamonde, Juan S. (author), Rubino, A. (author), Vitale, S. (author), and Colonna, Piero (author)

Abstract

High temperature Organic Rankine Cycles power systems of low power capacity, i.e. 3-50 kWe, are receiving recognition for distributed and mobile energy generation applications. For this type of power plants, it is customary to adopt a radial-turbine as prime mover, essentially for their ability to cope with very large volumetric flow ratio with limited fluid-dynamic penalty. To date, the design of such turbines is based on design guidelines and loss models developed mainly for turbo-chargers, subsequently adapted by means of non-validated computational fluid-dynamic calculations. In the attempt to provide data sets for CFD validation and calibration of loss models, a mini-ORC radial inflow turbine delivering 10kW of mechanical power will be realized and tested in the Propulsion and Power Laboratory of TU-Delft. The fluid dynamic design and characterization of the machine is detailed in this paper. According to available models, the results indicate that the optimal layout of mini-ORC turbines can substantially differ from that of radial-inflow turbines utilized in more traditional applications, strengthening the need of experimental campaigns to support the conception of new design practices., Flight Performance and Propulsion

Published
2017
Full Text
View/download PDF

162. Active subspaces for the optimal meanline design of unconventional turbomachinery

Author

Bahamonde, Juan S. (author), Pini, M. (author), de Servi, C.M. (author), Colonna, Piero (author), Bahamonde, Juan S. (author), Pini, M. (author), de Servi, C.M. (author), and Colonna, Piero (author)

Abstract

The preliminary fluid dynamic design of turbomachinery operating with non-standard working fluids and unusual operating conditions and specifications can be very challenging because of the lack of know-how and guidelines. Examples are the design of turbomachinery for small-capacity organic Rankine cycle and supercritical CO2 cycle power plants, whereby the efficiency of turbomachinery components has also a strong influence on the net conversion efficiency of the system. These machines operate with the fluid in thermodynamic states which, for part of the process, largely deviate from those obeying to the ideal gas law. This in turn implies the presence of so-called non-ideal compressible fluid dynamics effects. Active subspaces, a model reduction technique, is at the basis of the methodology presented here, which is aimed at the optimal meanline design of unconventional turbomachinery. The resulting surrogate model depends on a very small set of non-physical variables, called active variables. The procedure integrates into a single constrained optimization framework the selection of the working fluid, the thermodynamic cycle calculation and the preliminary sizing of the turbomachinery component. As a demonstration of the advantages of the proposed approach, the design of a 10kW mini organic Rankine cycle turbine with a turbine inlet temperature of 240°C is illustrated. In this case, approximately the same maximum efficiency is estimated for three dissimilar turbines operating with different working fluids and rather different thermodynamic cycles. The use of active subspaces allows the seamless evaluation of the sensitivity of results to input parameters, both those related to the machine and the working fluid. The novel design procedure is compared in terms of computational efficiency to a conventional approach based on the coupling of a genetic algorithm directly with a meanline code. Results show that the calculation based on the use of surrogate mod, Flight Performance and Propulsion

Published
2017
Full Text
View/download PDF

163. Multi-center experience using total lymphoid irradiation and anti-thymocyte globulin as conditioning for allografting in hematological malignancies

Author

Messina G, Giaccone L, Festuccia M, Irrera G, Scortechini I, Sorasio R, Gigli F, Passera R, Cavattoni I, Filippi AR, Schianca FC, Pini M, Selleri C, Levis A, Mordini N, Gallamini A, Pastano R, Casini M, Aglietta M, Montanari M, Console G, Boccadoro M, Ricardi U, Bruno B., RISITANO, ANTONIO MARIA, Messina, G, Giaccone, L, Festuccia, M, Irrera, G, Scortechini, I, Sorasio, R, Gigli, F, Passera, R, Cavattoni, I, Filippi, Ar, Schianca, Fc, Pini, M, Risitano, ANTONIO MARIA, Selleri, C, Levis, A, Mordini, N, Gallamini, A, Pastano, R, Casini, M, Aglietta, M, Montanari, M, Console, G, Boccadoro, M, Ricardi, U, and Bruno, B.

Published
2012

164. Long-term death and recurrence in patients with acute venous thromboembolism: the MASTER registry

Author

Ageno, W, Bellisi, M, Bianchi, M, Brancaccio, V, Ciampa, A, Cimminiello, C, Dragani, A, Grifoni, S, Imberti, D, Impagliatelli, A, Iovane, G, Margheriti, R, Grassi, G, Moia, M, Palareti, G, Pini, M, Pittaluga, P, Prisco, V, Rupoli, S, Scannapieco, G, Signorelli, S, Silingardi, M, MUSUMECI, Stefania, SIRAGUSA, Sergio, VIRGILIO, Vincenzo, Ageno, W, Bellisi, M, Bianchi, M, Brancaccio, V, Ciampa, A, Cimminiello, C, Dragani, A, Grifoni, S, Imberti, D, Impagliatelli, A, Iovane, G, Margheriti, R, Grassi, G, Moia, M, Musumeci, S, Palareti, G, Pini, M, Pittaluga, P, Prisco, V, Rupoli, S, Scannapieco, G, Signorelli, S, Silingardi, M, Siragusa, S, and Virgilio, V

Subjects
venous thromboembolism, Settore MED/15 - Malattie Del Sangue
Published
2012

165. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib

Author

Castagnetti, F, Gugliotta, G., Breccia, M., Stagno, F., Iurlo, A., Albano, F., Abruzzese, E., Martino, B., Levato, L., Intermesoli, T., Pregno, P., Rossi, G., Gherlinzoni, F., Leoni, P., Cavazzini, F., Venturi, C., Soverini, S., Testoni, N., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., Rosti, G., Baccarani, M., on behalf of the GIMEMA CML Working Party (Lucarelli, G., Polimeno, G., Ladetto, M., Pini, M., Rupoli, S., Scortechini, A. R., Galieni, P., Bigazzi, C., Cantore, N., Palmieri, F., Specchia, G., Russo, Rossi., Rambaldi, A., Ferrari, M. L., Palandri, F., Luatti, S., Iacobucci, I., Bochicchio, M. T., Apolinari, M., Fogli, M., Cervello, I., Capucci, A., Giuliani, G., Malpignano, A., Girasoli, M., Angelucci, E., Usala, E., De Biasi, E., Tagariello, G., Sartori, R., Di Raimondo, F., Vigneri, P., Molica, S., Lentini, M., Lanza, F., Viganò, C., Grasso, M., Rapezzi, D., Cuneo, A., Ciccone, M., Bosi, A., Gozzini, A., Gobbi, M., Pierri, I., Chianese, R., De Blasio, A., Ciccone, F., Capochiani, E., Pelosini, M., Musolino, C., Russo, S., Cortelezzi, A., Luppi, M., Marasca, R., Pogliani, E. M., Gambacorti-Passerini, C., Luciano, L., Izzo, B., Ferrara, F., Annunziata, M., Mettivier, V., Sessa, U., Latte, G., Noli, D., Rege-Cambrin, G., Fava, C., Semenzato, G., Binotto, G., Fabbiano, F., Turri, D., Siragusa, S., Caracciolo, C., Musso, M., Porretto, F., Cazzola, M., Orlandi, E., Falini, B., Falzetti, F., Visani, G., Isidor, I., Di Bartolomeo, P., Di Lorenzo, R., Vallisa, D., Trabacch, I., Pizzuti, M., Zuffa, E., Salvucci, M., Ronco, F., Lelo, D., Merli, F., Avanzini, P., Tosi, P., Merli, A., Sica, S., Sorà, F., Latagliata, R., De Fabritiis, P., Trawiska, M., Amadori, S., Cantonetti, M., Majolino, I., Pacilli, L., Ronci, B., Cedrone, M., Mengarelli, A., Romano, A., Tafuri, A., Montefusc, O., Iuliano, F., Infusino, S., Dore, F., Fozza, C., Bocchia, M., Defina, M., Liberati, Am., Luzi, D., Boccadoro, M., Ferrero, D., Vitolo, U., Nicolosi, M., Gottardi, M., Calistri, E., Fanin, R., Tiribelli, M., Pizzolo, G., Bonifacio, M., Rodeghiero, F., Di Bona, E. )., Castagnetti, F, Gugliotta, G., Breccia, M., Stagno, F., Iurlo, A., Albano, F., Abruzzese, E., Martino, B., Levato, L., Intermesoli, T., Pregno, P., Rossi, G., Gherlinzoni, F., Leoni, P., Cavazzini, F., Venturi, C., Soverini, S., Testoni, N., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., Rosti, G., Baccarani, M., and on behalf of the GIMEMA CML Working Party [, Palandri F.], Pane, Fabrizio, Gugliotta, G, Breccia, M, Stagno, F, Iurlo, A, Albano, F, Abruzzese, E, Martino, B, Levato, L, Intermesoli, T, Pregno, P, Rossi, G, Gherlinzoni, F, Leoni, P, Cavazzini, F, Venturi, C, Soverini, S, Testoni, N, Alimena, G, Cavo, M, Martinelli, G, Pane, F, Saglio, G, Rosti, G, Baccarani, M, and GAMBACORTI PASSERINI, C

Subjects
DIAGNOSED CHRONIC-PHASE, Oncology, Male, Cancer Research, Time Factors, bcr-abl, Fusion Proteins, bcr-abl, Antineoplastic Agent, Hematology, Anesthesiology and Pain Medicine, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Cumulative incidence, Young adult, Chronic, Aged, 80 and over, Leukemia, PATIENTS RECEIVING IMATINIB, CHRONIC MYELOGENOUS LEUKEMIA, TYROSINE KINASE INHIBITORS, BCR-ABL1 TRANSCRIPT LEVELS, EARLY MOLECULAR RESPONSE, CML WORKING PARTY, 3-YEAR FOLLOW-UP, EUROPEAN LEUKEMIANET, 400 MG, Myeloid leukemia, Middle Aged, Prognosis, Treatment Outcome, Retreatment, Imatinib Mesylate, Female, Tyrosine kinase, Human, medicine.drug, Adult, medicine.medical_specialty, Time Factor, Adolescent, Prognosi, Protein Kinase Inhibitor, Socio-culturale, Antineoplastic Agents, Treatment results, Follow-Up Studie, Young Adult, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Internal medicine, medicine, Humans, Protein Kinase Inhibitors, Aged, Antineoplastic Combined Chemotherapy Protocol, business.industry, Fusion Proteins, Imatinib, Follow-Up Studies, Surgery, Imatinib mesylate, BCR-ABL Positive, business, Myelogenous
Abstract

For almost 10 years imatinib has been the therapeutic standard of chronic myeloid leukemia. The introduction of other tyrosine kinase inhibitors (TKIs) raised a debate on treatment optimization. The debate is still heated: some studies have protocol restrictions or limited follow-up; in other studies, some relevant data are missing. The aim of this report is to provide a comprehensive, long-term, intention-to-treat, analysis of 559 newly diagnosed, chronic-phase, patients treated frontline with imatinib. With a minimum follow-up of 66 months, 65% of patients were still on imatinib, 19% were on alternative treatment, 12% died and 4% were lost to follow-up. The prognostic value of BCR-ABL1 ratio at 3 months (⩽10% in 81% of patients) was confirmed. The prognostic value of complete cytogenetic response and major molecular response at 1 year was confirmed. The 6-year overall survival was 89%, but as 50% of deaths occurred in remission, the 6-year cumulative incidence of leukemia-related death was 5%. The long-term outcome of first-line imatinib was excellent, also because of second-line treatment with other TKIs, but all responses and outcomes were inferior in high-risk patients, suggesting that to optimize treatment results, a specific risk-adapted treatment is needed for such patients.

Published
2015

166. A refined composite clinical score for the early identification of the predicted Poor Mobilizers (PM): a GITMO analysis

Author

Attolico, I., Olivieri, J., Nuccorini, R., Pascale, S. P., Chiarucci, M., Poiani, M., Gozzer, M., Capria, S., Mele, G., Melpignano, A., Perseghin, P., Pioltelli, P., Massimo Martino, Moscato, T., Musto, P., Pietrantuono, G., Corradini, P., Farina, L., Nassi, L., Casaluci, G. Margiotta, Di Marco, A., Spadaro, A., Gumenyuku, S., Marchesi, F., Lanza, F., Brambilla, P., Pini, M., Zallio, F., Marktel, S., Gattillo, S., Sica, S., Ausoni, G., Merli, F., Codeluppi, K., Specchia, G., Pastore, D., Pizzuti, M., Di Nardo, E., and Olivieri, A.

Published
2015

169. Myeloablative, reduced toxicity versus standard conditioning in AML: a randomized clinical trial from Gruppo Italiano Trapianto di Midollo Osseo (GITMO)

Author

Grassi, A., Mico, C., Oldani, E., Boschini, C., Busca, A., Benedetto, B., Cavattoni, I., Santarone, S., Raimondi, R., Montanari, M., Milone, G., Patrizia Chiusolo, Specchia, G., Guidi, S., Patriarca, F., Bacigalupo, A., Risitano, A. M., Saporiti, G., Pini, M., Pogliani, E. M., Arcese, W., Marotta, G., Carella, A. M., Nagler, A., Corradini, P., Russo, D., Alessandrino, E. P., Torelli, G. F., Mordini, N., Scime, R., Bosi, A., Masciulli, A., Marfisi, R. M., and Rambaldi, A.

Published
2015

170. Le PMI del Mezzogiorno nel tunnel della crisi

Author

Capuano, G, Rinaldi, A: Cortese, P, Vacca, S, Cacciaglia, R, Giusti, G, Pini, M, Ciciotti, E, Dallara, A, Rizzi, P, MAZZOLA, Fabio, Unioncamere, Istituto Tagliacarne, Capuano, G, Rinaldi, A: Cortese, P, Vacca, S, Cacciaglia, R, Giusti, G, Pini, M, Ciciotti, E, Dallara, A, Rizzi, P, and Mazzola, F

Subjects
piccola e media impresa, Mezzogiorno, crisi economica
Abstract

Il lavoro analizza la dinamica delle PMI meridionali nel periodo della crisi (ultimo trimestre 2008 e 2009) mettendola a confronto con quella media nazionale, anche con riferimento ai segmenti più dinamici dell’industria meridionale che si presentano come i più idonei a fronteggiare i principali effetti della crisi e a fornire risposte in merito all’avvio di processi di ristrutturazione produttiva. In tal senso, si esamina l’andamento aggregato delle PMI meridionali nel periodo della crisi, confrontando la dinamica di tali imprese con quella delle PMI centro-settentrionali e successivamente ci si sofferma sulle dinamiche manifestate dalle PMI nei diversi settori e sulle eventuali risposte differenziali alla crisi da parte delle piccole imprese (da 6 a 49 addetti) e delle medie imprese (da 50 a 250 addetti). Ci si concentra quindi su tre segmenti particolarmente avanzati del tessuto produttivo meridionale osservandone la risposta al periodo di crisi in rapporto a quanto avviene per le imprese appartenenti agli stessi segmenti localizzate nel Centro-Nord. In sintonia con la letteratura esistente sulla “middle class” di impresa, i segmenti presi in considerazione sono quello delle imprese facenti parte di gruppi, quello delle imprese che esportano e le società di capitali. Nel paragrafo conclusivo si effettuano alcune considerazioni di policy.

Published
2009

171. A commentary: To screen for calf DVT or not to screen? The highly variable practice among italian centers highlights this important and still unresolved clinical opinion. Results from the italian MASTER registry

Author

PALARETI G, AGNELLI G, IMBERTI D, MOIA M, AGENO W, PISTELLI R, VERSO M, BELLISI M, BIANCHI M, BRANCACCIO V, CAPONI C, CIAMPA A, CIMMINIELLO C, DRAGANI A, GRIFONI S, IMPAGLIATELLI AM, IOVANE G, MARGHERITI R, MUSUMECI S, PINI M, PITTALUGA PA, PRISCO V, RUPOLI S, SCANNAPIECO G, SIGNORELLI SS, ILINGARDI M, SIRAGUSA, Sergio, VIRGILIO, Vincenzo, PALARETI G, AGNELLI G, IMBERTI D, MOIA M, AGENO W, PISTELLI R, VERSO M, BELLISI M, BIANCHI M, BRANCACCIO V, CAPONI C, CIAMPA A, CIMMINIELLO C, DRAGANI A, GRIFONI S, IMPAGLIATELLI AM, IOVANE G, MARGHERITI R, MUSUMECI S, PINI M, PITTALUGA PA, PRISCO V, RUPOLI S, SCANNAPIECO G, SIGNORELLI SS, ILINGARDI M, SIRAGUSA S, and VIRGILIO V

Subjects
calf deep vein thrombosis, Settore MED/15 - Malattie Del Sangue
Published
2008

172. The MASTER registry on venous thromboembolism: description of the study cohort

Author

AGNELLI G, VERSO M, AGENO W, IMBERTI D, MOIA M, PALARETI G, ROSSI R, PISTELLI R. MASTER INVESTIGATORS AGNELLI G, BELLISI M, BIANCHI M, BRANCACCIO V, CAPONI C, CIAMPA A, CIMMINIELLO C, DRAGANI A, GRIFONI S, IMPAGLIATELLI AM, IOVANE G, MARGHERITI R, MUSUMECI S, PINI M, PITTALUGA PA, PRISCO V, RUPOLI S, SCANNAPIECO G, SIGNORELLI SS, SILINGARDI M, SIRAGUSA, Sergio, VIRGILIO, Vincenzo, AGNELLI G, VERSO M, AGENO W, IMBERTI D, MOIA M, PALARETI G, ROSSI R, PISTELLI R MASTER INVESTIGATORS AGNELLI G, BELLISI M, BIANCHI M, BRANCACCIO V, CAPONI C, CIAMPA A, CIMMINIELLO C, DRAGANI A, GRIFONI S, IMPAGLIATELLI AM, IOVANE G, MARGHERITI R, MUSUMECI S, PINI M, PITTALUGA PA, PRISCO V, RUPOLI S, SCANNAPIECO G, SIGNORELLI SS, SILINGARDI M, SIRAGUSA S, and VIRGILIO V

Subjects
veonus thrombosis, registry, Settore MED/15 - Malattie Del Sangue
Published
2008

173. Frontal polymerization: a new approach to the consolidation of stone?

Author

Mariani A., Brunetti A., Bidali S., Alzari V., Caria G., Nuvoli D., Pini M., CAPPELLETTI, PIERGIULIO, COLELLA, ABNER, Delgado Rodriguez J., Mimoso J.M., Mariani, A., Cappelletti, Piergiulio, Brunetti, A., Bidali, S., Alzari, V., Caria, G., Colella, Abner, Nuvoli, D., and Pini, M.

Published
2008

174. Factors associated with the timing of diagnosis of venous thromboembolism: results from the MASTER registry

Author

Ageno, W, Agnelli, G, Imberti, D, Moia, M, Palareti, G, Pistelli, R, Rossi, R, Vitale, J, Bellisi, M, Bianchi, M, Verso, M, Brancaccio, V, Ciampa, A, Cimminiello, C, Dragani, A, Grifoni, S, Impaglatelli, M, Margheriti, R, Iovane, G, Musumeci, A, Pini, M, Pittaluga, PA, Prisco, V, Rupoli, S, Scannapieco, G, Signorelli, S, Silingardi, M, Virgilio, V., SIRAGUSA, Sergio, Ageno, W, Agnelli, G, Imberti, D, Moia, M, Palareti, G, Pistelli, R, Rossi, R, Vitale, J, Bellisi, M, Bianchi, M, Verso, M, Brancaccio, V, Ciampa, A, Cimminiello, C, Dragani, A, Grifoni, S, Impaglatelli, M, Margheriti, R, Iovane, G, Musumeci, A, Pini, M, Pittaluga, PA, Prisco, V, Rupoli, S, Scannapieco, G, Signorelli, S, Silingardi, M, Siragusa, S, and Virgilio, V

Subjects
venous thrombosis, timing, diagnosis, Settore MED/15 - Malattie Del Sangue
Abstract

INTRODUCTION: Signs and symptoms of venous thromboembolism (VTE) are non-specific and thus can make diagnosis difficult, even for an experienced clinician. We aimed to evaluate the timing of diagnosis of deep vein thrombosis (DVT) and pulmonary embolism (PE) in Italian hospitals and to identify individual and clinical predictors of timely or delayed diagnosis. MATERIAL AND METHODS: MASTER is a multicenter prospective registry of patients with acute DVT and PE. Information on clinical presentation and diagnostic methods, temporary and permanent risk factors, were captured by an electronic data network at the time of the index event. RESULTS: Data on 2047 patients (1024 males), 1505 with DVT and 542 with PE, were analysed. Delayed diagnosis (i.e. more than 10 days from onset of symptoms) was observed in 340 (22.6%) patients with DVT and in 88 (16.2%) with PE, respectively. In DVT patients, factors associated with earlier diagnosis were the presence of multiple signs or symptoms (p=0.014), the presence of pain (p=0.049), and previous venous thrombosis (p=0.016). Neither the presence of other known risk factors nor ongoing prophylaxis influenced the timing of diagnosis. In PE patients, only multiple signs or symptoms at presentation (p=0.014) and the presence of transient risk factors (p=0.001) were significantly associated with earlier diagnosis. CONCLUSIONS: Substantial delays occur when diagnosing both DVT and PE. The severity of presentation, but not patient risk profile are associated with earlier diagnosis, even in patients with signs or symptoms of PE.

Published
2008

175. Anthropometric measures, medical history and risk of basal cell carcinoma in an Italian case-control study

Author

Pelucchi C, Naldi L, Di Landro A, La Vecchia C, Betti R, Inselvini E, Crosti C, Rossi E, Pini M, Galbiati G, Ceschini R, Simonacci M, Virgili A, Lombardi A, Braga D, Puiatti P, Bonvicino A, Lo Schiavo A, Sarracco G, Barile M, Feliciangeli M, Barba A, Cattoni D, Pestelli F, Carli P, Cusano F, Adamo F, Sclamich S, Magaton Rizzi G, Filotico R., FABBROCINI, GABRIELLA, Pelucchi, C, Naldi, L, Di Landro, A, La Vecchia, C, Betti, R, Inselvini, E, Crosti, C, Rossi, E, Pini, M, Galbiati, G, Ceschini, R, Simonacci, M, Virgili, A, Lombardi, A, Braga, D, Puiatti, P, Bonvicino, A, Lo Schiavo, A, Fabbrocini, Gabriella, Sarracco, G, Barile, M, Feliciangeli, M, Barba, A, Cattoni, D, Pestelli, F, Carli, P, Cusano, F, Adamo, F, Sclamich, S, Magaton Rizzi, G, Filotico, R., LO SCHIAVO, Ada, and e. t., C.

Subjects
Male, medicine.medical_specialty, Skin Neoplasms, case-control study, body mass index, Dermatology, Diabetes Complications, epidemiology medical history, basal cell carcinoma, Internal medicine, medicine, Humans, risk factors, Body Weights and Measures, Basal cell carcinoma, Obesity, Risk factor, skin and connective tissue diseases, Aged, Body surface area, Anthropometry, integumentary system, business.industry, Case-control study, Odds ratio, Middle Aged, Thoracic Neoplasms, medicine.disease, Trunk, medical history, Asthma, Surgery, Logistic Models, Italy, Carcinoma, Basal Cell, Head and Neck Neoplasms, Case-Control Studies, Sunlight, Female, epidemiology, business, case-control studie, Body mass index
Abstract

Background/Aims: A few epidemiological studies investigated etiological factors for basal cell carcinoma (BCC) other than sunlight exposure and sunburns. Information on anthropometric measures and medical history is scant. Methods: We examined the issue in a case-control study including 528 patients with incident, histologically confirmed BCC and 512 controls hospitalized with acute conditions. Results: Odds ratios (OR) for the highest versus the lowest quartiles were 0.77 for weight, 0.99 for height, 0.87 for body mass index and 0.81 for body surface area. Corresponding estimates for trunk BCC were 0.42, 0.81, 0.50 and 0.47. Subjects with asthma (OR = 0.26) and diabetes mellitus (OR = 0.23) showed a decreased risk of trunk BCC but not face and neck BCC. Conclusion: The inverse relations between trunk, but not face and neck BCC, and obesity, diabetes mellitus and asthma may indirectly reflect the different role of past sunlight exposure to different body locations and variable etiologic pathways for BCCs according to body areas.

Published
2008

176. Active subspaces for the preliminary fluid dynamic design of unconventional turbomachinery

Author

Bahamonde, Juan S. (author), Pini, M. (author), Colonna, Piero (author), Bahamonde, Juan S. (author), Pini, M. (author), and Colonna, Piero (author)

Abstract

The fluid dynamic preliminary design of unconventional turbomachinery is customary done with meanline design procedures coupled with gradient-free optimizers. This method features various drawbacks, since it might become computationally expensive, and it does not provide design insights or guidelines to the designer. This work proposes a strategy to abate this disadvantages, namely, the construction of a reduced-order model by means of active sub-spaces, and the use of the surrogate combined with a gradient-based optimizer. The case study is the design optimization of a Organic Rankine Cycle radial inflow turbine. The results show that active subspaces exist for this application, and that it is possible to construct a surrogate with an approximate error of ±1% for the total-to-static efficiency. Additionally, the optimization using the surrogate leads to accurate results and a computational cost at least four times faster. Furthermore, the results reveal that the models for unconventional turbomachinery feature multiple regions containing constrained optima. Active subspace methods thus prove to be a promising alternative for optimization of unconventional turbomachinery., Flight Performance and Propulsion

Published
2016

181. Rotatable magnetic anisotropy in a Fe0.8Ga0.2 thin film with stripe domains: Dynamics versus statics

Author

Tacchi, S., Fin, S., Carlotti, G., Gubbiotti, G., Madami, M., Barturen, M., Marangolo, Massimiliano, Eddrief, Mahmoud, Bisero, D., Rettori, A., Pini, M. G., Institut des Nanosciences de Paris (INSP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), and MIUR under PRIN [2010ECA8P3]

Subjects
perpendicular anisotropy, NI-FE, exchange bias, multilayers, Condensed Matter::Superconductivity, Condensed Matter::Strongly Correlated Electrons, [PHYS.COND]Physics [physics]/Condensed Matter [cond-mat], perpendicular anisotropy,exchange bias, NI-FE, multilayers, NO
Abstract

International audience; A comprehensive investigation of rotatable anisotropy in a Fe0.8Ga0.2 thin film with a stripe domain structure has been performed comparing static and dynamic measurements. The stripes' domain formation and their rotation under a transverse magnetic field have been imaged by magnetic force microscopy. The rotatable anisotropy field H-rot was determined by fitting the frequency evolution of the dipole-dominated magnetostatic spin-wave mode versus the in-plane orientation of the stripe domains, measured by Brillouin light scattering in the absence of any dc or ac magnetic field. We obtained H-rot approximate to 1.35 kOe, which is nearly ten times larger than the crystallographic in-plane anisotropy field. By applying a dc magnetic field along the stripes' axis, H-rot decreases, and eventually vanishes for saturated in-plane magnetization. At remanence, we established a quantitative relationship between static and dynamic properties, that is, the stripes' rotation angle and the in-plane angle dependence of spin-wave frequency.

Published
2014
Full Text
View/download PDF

182. Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry

Author

Piaserico, Stefano, Cazzaniga, Simone, Chimenti, Sergio, Giannetti, Alberto, Maccarone, Mara, Picardo, Mauro, Peserico, Andrea, Naldi, Luigi, Griseta, V., Miracapillo, A., Azzini, M., Mocci, L., Michelini, M., Offidani, A., Bernardini, L., Campanati, A., Ricotti, G., Giacchetti, A., Norat, M., Gualco, F., Castelli, A., Cuccia, A., Diana, A., Roncarolo, G., Belli, M. A., Baldassarre, M. A., Santoro, G., Vena, G. A., Lo Console, F., Filotico, R., Mastrandrea, V., Brunetti, B., Musumeci, F., Carrabba, E., Dal Mas, P., Annicchiarico, F., Benvegnã¹, B., Spaziani, G., Cusano, F., Saletta Iannazzone, S., Galluccio, A., Pezza, M., Marchesi, L., Imberti, G., Reseghetti, A., Barbera, C., Reggiani, M., Lanzoni, A., Patrizi, A., Bardazzi, F., Antonucci, A., De Tommaso, S., Balestri, R., Wallnofer, W., Ingannamorte, F., Calzavara-Pinton, P., Iannazzi, S., Zane, C., Capezzera, R., Bassisi, S., Rossi, M. T., Altamura, V., Vigl, W., Nobile, C., Aste, N., Murgia, S., Mugheddu, C., Scuderi, G., Baglieri, F., Di Dio, C., Cilioni Grilli, E., Mastronardi, C., Agnusdei, C. P., Antrilli, A., Aulisa, L., Raimondo, U., Scotto di Luzio, G., Battarra, V. C., Farro, P., Plaitano, R., Micali, G., Musumeci, M. L., Massimino, D., Li Calzi, M., La Greca, S., Pettinato, M., Sapienza, G., Valenti, G., De Giacomo, P. F., D’amico, D., Arcangeli, F., Brunelli, D., Ghetti, E., Tulli, A., Assi, G., Amerio, P., Laria, G., Prestinari, F., Spadafora, S., Coppola, M., Caresana, G., Pezzarossa, E., Domaneschi, E., Felisi, C., Donato, L., Bertero, M., Musso, L., Pa lazzini, S., Bruscino, P., Agozzino, U. C., Ottaviani, M., Simoncini, C., Virgili, A., Osti, F., Fabbri, P., Volpi, W., Caproni, M., Lotti, T., Prignano, F., Buggiani, G., Troiano, M., Fenizi, G., Altobella, A., Amoruso, A., Condello, M., Goffredo, A., Righini, M. G., Alessandrini, F., Satolli, F., Zampetti, M., Bertani, E., Fossati, S., Parodi, A., Burlando, M., Fiorucci, C., Nigro, A., Ghigliotti, G., Massone, L., Moise, G. M., Serrai, M., Cannata, G., Campagnoli, A. M., Daly, M., Leporati, C., Peila, R., Filosa, G., Bugatti, L., Nicolini, M., Nazzari, G., Cestari, R., Anastasio, F., Larussa, F. M., Pollice, N., De Francesco, F., Mazzocchetti, G., Peris, K., Fargnoli, M. C., Di Cesare, A., De Angelis, L., Flati, G., Biamonte, A. S., Quarta, G., Congedo, M., Carcaterra, A., Strippoli, D., Fideli, D., Marsili, F., Celli, M., Ceccarini, M., Bachini, L., D’oria, M., Schirripa, V., De Filippi, C., Martini, P., Lapucci, E., Mazzatenta, C., Ghilardi, A., Simonacci, M., Bettacchi, A., Gasco, R., Zanca, A., Battistini, S., Dattola, S., Vernaci, R., Postorino, F., Zampieri, P. F., Padovan, C., González Intchaurraga, M. A., Ladurner, J., Guarneri, B., Cannavo', S., Manfrã, C., Borgia, F., Puglisi Guerra, A., Sedona, P., Cattaneo, A., Carrera, C., Fracchiolla, C., Mozzanica, N., Prezzemolo, L., Menni, S., Lodi, A., Martino, P., Monti, M., Mancini, L., Sacrini, F., Altomare, G. F., Taglioni, M., Lovati, C., Mercuri, S. R., Schiesari, G., Giannetti, A., Conti, A., Lasagni, C., Greco, M., Ronsini, G., Schianchi, S., Fiorentini, C., Niglietta, S., Maglietta, R., Padalino, C., Crippa, D., Pini, M., Rossi, E., Tosi, D., Armas, M., Ruocco, V., Ayala, F., Balato, N., Gaudiello, F., Cimmino, G. F., Monfrecola, G., Gallo, L., Argenziano, G., Fulgione, E., Berruti, G., Ceparano, S., De Michele, I., Giorgiano, D., Leigheb, G., Deledda, S., Peserico, A., Alaibac, M., Piaserico, S., Schiesari, L., Dan, G., Mattei, I., Oro, E., Aricã², M., Bongiorno, M. R., Angileri, R., Amato, S., Todaro, F., Milioto, M., Bellastro, R., Di Nuzzo, S., De Panfilis, G., Zanni, M., Borroni, G., Cananzi, R., Brazzelli, V., Lisi, P., Stingeni, L., Hansel, K., Pierfelice, V., Donelli, S., Rastelli, D., Gasperini, M., Barachini, P., Cecchi, R., Bartoli, L., Pavesi, M., De Paola, S., Corradin, M. T., Ricciuti, F., Piccirillo, A., Viola, L., Tataranni, M., Mautone, M. G., Lo Scocco, G., Niccoli, M. C., Brunasso Vernetti, A. M. G., Gaddoni, G., Resta, F., Casadio, M. C., Arcidiaco, M. C., Luvarã , M. C., Albertini, G., Di Lernia, V., Guareschi, E., Catrani, S., Morri, M., De Simone, C., D’agostino, M., Agostino, I., Calvieri, S., Cantoresi, F., Richetta, A., Sorgi, P., Carnevale, C., Nicolucci, F., Berardesca, E., Ardigã², M., De Felice, C., Gubinelli, E., Chimenti, S., Talamonti, M., Camplone, G., Cruciani, G., Riccardi, F., Barbati, R., Zumiani, G., Pagani, W., Malagoli, P. G., Pellicano, R., Donadio, D., Di Vito, C., Cottoni, F., Montesu, M. A., Pirodda, C., Addis, G., Marongiu, P., Farris, A., Cacciapuoti, M., Verrini, A., Desirello, G., Gnone, M., Fimiani, M., Pellegrino, M., Castelli, G., Zappalã , L., Sesana, G., Ingordo, V., Vozza, E., Di Giuseppe, D., Fasciocco, D., Nespoli, P., Papini, M., Cicoletti, M., Bernengo, M. G., Ortoncelli, M., Bonvicino, A., Capella, G., Doveil, G. C., Forte, M., Peroni, A., Salomone, B., Savoia, P., Pippione, M., Zichichi, L., Frazzitta, M., De Luca, G., Tasin, L., Simonetto, D., Ros, S., Trevisan, G., Patamia, M., Miertusova, S., Patrone, P., Frattasio, A., Piccirillo, F., La Spina, S., Di Gaetano, L., Marzocchi, V., Motolese, A., Venturi, C., Gai, F., Pasquinucci, S., Bellazzi, R. M., Silvestri, T., Girolomoni, G., Gisondi, P., Veller Fornasa, C., Trevisan, G. P., Piaserico S, Cazzaniga S, Chimenti S, Giannetti A, Maccarone M, Picardo M, Peserico A, Naldi L, Psocare Study Group [.., Patrizi A, ], Piaserico, S, Cazzaniga, S, Chimenti, S, Giannetti, A, Maccarone, M, Picardo, M, Peserico, A, Naldi, L, Bongiorno, MR, Psocare Study Group, Monfrecola, Giuseppe, and Trevisan, Giusto

Subjects
Male, primary inefficacy, 75% improvement in the Psoriasis Area Severity Index score, PASI, PASI 75, Psoriasis Area Severity Index, TNF, biologics, efficacy, psoriasis, secondary loss of efficacy, switching, tumor necrosis factor, tumor necrosis factor-alfa inhibitors, Adult, Analysis of Variance, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Cohort Studies, Confidence Intervals, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Immunoglobulin G, Italy, Middle Aged, Multivariate Analysis, Predictive Value of Tests, Proportional Hazards Models, Psoriasis, Receptors, Tumor Necrosis Factor, Registries, Retrospective Studies, Risk Assessment, Severity of Illness Index, Treatment Outcome, Tumor Necrosis Factor-alpha, Young Adult, SWITHCES, psoriasis arthritis, pharmachological treatment, Etanercept, Monoclonal, Receptors, Settore MED/35 - Malattie Cutanee E Veneree, Humanized, Hazard ratio, Predictive value of tests, Drug, biologic, TNF-alpha, medicine.medical_specialty, Dermatology, Antibodies, Dose-Response Relationship, Settore MED/35, Internal medicine, Severity of illness, medicine, Adverse effect, psoriasi, Adalimumab, Infliximab, 2708, Proportional hazards model, business.industry, tumor necrosis factor-alfa inhibitor, Retrospective cohort study, medicine.disease, Confidence interval, Surgery, ANTI-TNFA, business
Abstract

Background: Some studies have shown that switching patients from one tumor necrosis factor (TNF)-alfa inhibitor to another may be beneficial when they have an inadequate response or an adverse event. Objective: We sought to assess the variables predicting the efficacy of the second TNF-alfa inhibitor in patients discontinuing the first TNF-alfa inhibitor. Methods: Data from all 5423 consecutive patients starting TNF-alfa inhibitor therapy for psoriasis between September 2005 and September 2010 who were included in the Italian Psocare registry were analyzed. Results: In 105 patients who switched to a second TNF-alfa inhibitor who had complete follow-up data, 75% improvement in the Psoriasis Area Severity Index score (PASI 75) was reached by 29% after 16 weeks and by 45.6% after 24 weeks. Patients who switched because of secondary loss of efficacy (loss of initial PASI 75 response) or adverse events/intolerance were more likely to reach PASI 75 than those who switched as a result of primary inefficacy (PASI 75 never achieved) (hazard ratio 2.7, 95% confidence interval 1.3-5.5 vs hazard ratio 2.0, 95% confidence interval 1.0-3.9 and 1, respectively). Limitations: There was a small number of patients with complete follow-up data. Conclusion: PASI 75 response in patients who switched from one antie-TNF-alfa agent to another was significantly reduced in patients who showed primary inefficacy of the first antie-TNF-alfa.

Published
2014

183. A Framework for Aggregating Influenced CP-nets and Its Resistance to Bribery

Author

ALBERTO MARAN, Maudet, N., Pini, M. S., Rossi, F., Venable, K. B., Systèmes Multi-Agents (SMA), Laboratoire d'Informatique de Paris 6 (LIP6), Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), and Publications, Lip6

Subjects
[INFO]Computer Science [cs], General Medicine, [INFO] Computer Science [cs]
Abstract

We consider multi-agent settings where a set of agents want to take a collective decision, based on their preferences over the possible candidate options. While agents have their initial inclination, they may interact and influence each other, and therefore modify their preferences, until hopefully they reach a stable state and declare their final inclination. At that point, a voting rule is used to aggregate the agents’ preferences and generate the collective decision. Recent work has modeled the influence phenomenon in the case of voting over a single issue. Here we generalize this model to account for preferences over combinatorially structured domains including several issues. We propose a way to model influence when agents express their preferences as CP-nets. We define two procedures for aggregating preferences in this scenario, by interleaving voting and influence convergence, and study their resistance to bribery.

Published
2013

185. Domain-induced anomaly of the spin-wave frequency in perpendicularly magnetized Ni(001) ultrathin films.

Author

Gubbiotti, G., Albini, L., Carlotti, G., Pini, M. G., Politi, P., Rettori, A., Vavassori, P., Ciria, M., Ha, K., and O'Handley, R. C.

Subjects
MAGNETIC films, ANISOTROPY, EPITAXY
Abstract

Epitaxial Cu/Ni/Cu/Si(001) magnetic films have been studied in the thickness range (17-120 Å) where a uniaxial anisotropy favoring the direction perpendicular to the film plane is dominant over the easy-plane dipolar interaction. Using magneto-optic magnetometry and Brillouin light scattering we show that on decreasing an in-plane magnetic field the perpendicular component of the magnetization breaks into domains. © 2001 American Institute of Physics. [ABSTRACT FROM AUTHOR]

Published
2001
Full Text
View/download PDF

188. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: Evidence from the Italian Psocare Registry

Author

Gisondi, P., Cazzaniga, S., Chimenti, S., Giannetti, A., Maccarone, M, Picardo, M., Girolomoni, G., Naldi, L., Griseta, V, Miracapillo, A, Azzini, M, Mocci, L, Michelini, M, Offidani, A, Bernardini, L, Campanati, A, Ricotti, G, Giacchetti, A, Norat, M, Gualco, F, Castelli, A, Cuccia, A, Diana, A, Roncarolo, G, Belli, Ma, Baldassarre, Ma, Santoro, G, Vena, Ga, Lo Console, F, Filotico, R, Mastrandrea, V, Brunetti, B, Musumeci, F, Carrabba, E, Dal Mas, P, Annicchiarico, F, Benvegnù, B, Spaziani, G, Cusano, F, Saletta Iannazzone, S, Galluccio, A, Pezza, M, Marchesi, L, Imberti, G, Reseghetti, A, Barbera, C, Reggiani, M, Lanzoni, A, Patrizi, A, Bardazzi, F, Antonucci, A, De Tommaso, S, Balestri, R, Wallnofer, W, Ingannamorte, F, Calzavara-Pinton, P, Iannazzi, S, Zane, C, Capezzera, R, Bassisi, S, Rossi, Mt, Altamura, V, Vigl, W, Nobile, C, Aste, N, Murgia, S, Mugheddu, C, Scuderi, G, Baglieri, F, Di Dio, C, Cilioni Grilli, E, Mastronardi, C, Agnusdei, Cp, Antrilli, A, Aulisa, L, Raimondo, U, Scotto di Luzio, G, Battarra, Vc, Farro, P, Plaitano, R, Micali, G, Musumeci, Ml, Massimino, D, Li Calzi, M, La Greca, S, Pettinato, M, Sapienza, G, Valenti, G, De Giacomo PF, D'Amico, D, Arcangeli, F, Brunelli, D, Ghetti, E, Tulli, A, Assi, G, Amerio, P, Laria, G, Prestinari, F, Spadafora, S, Coppola, M, Caresana, G, Pezzarossa, E, Domaneschi, E, Felisi, C, Donato, L, Bertero, M, Musso, L, Pa lazzini, S, Bruscino, P, Agozzino, Uc, Ottaviani, M, Simoncini, C, Virgili, A, Osti, F, Fabbri, P, Volpi, W, Caproni, M, Lotti, T, Prignano, F, Buggiani, G, Troiano, M, Fenizi, G, Altobella, A, Amoruso, A, Condello, M, Goffredo, A, Righini, Mg, Alessandrini, F, Satolli, F, Zampetti, M, Bertani, E, Fossati, S, Parodi, A, Burlando, M, Fiorucci, C, Nigro, A, Ghigliotti, G, Massone, L, Moise, Gm, Serrai, M, Cannata, G, Campagnoli, Am, Daly, M, Leporati, C, Peila, R, Filosa, G, Bugatti, L, Nicolini, M, Nazzari, G, Cestari, R, Anastasio, F, Larussa, Fm, Pollice, N, De Francesco, F, Mazzocchetti, G, Peris, K, Fargnoli, Mc, Di Cesare, A, De Angelis, L, Flati, G, Biamonte, As, Quarta, G, Congedo, M, Carcaterra, A, Strippoli, D, Fideli, D, Marsili, F, Celli, M, Ceccarini, M, Bachini, L, D'Oria, M, Schirripa, V, De Filippi, C, Martini, P, Lapucci, E, Mazzatenta, C, Ghilardi, A, Simonacci, M, Bettacchi, A, Gasco, R, Zanca, A, Battistini, S, Dattola, S, Vernaci, R, Postorino, F, Zampieri, Pf, Padovan, C, González Intchaurraga MA, Ladurner, J, Guarneri, B, Cannavò, S, Manfrè, C, Borgia, F, Puglisi Guerra, A, Sedona, P, Cattaneo, A, Carrera, C, Fracchiolla, C, Mozzanica, N, Prezzemolo, L, Menni, S, Lodi, A, Martino, P, Monti, M, Mancini, L, Sacrini, F, Altomare, F, Taglioni, M, Lovati, C, Mercuri, Sr, Schiesari, G, Giannetti, A, Conti, A, Lasagni, C, Greco, M, Ronsini, G, Schianchi, S, Fiorentini, C, Niglietta, S, Maglietta, R, Padalino, C, Crippa, D, Pini, M, Rossi, E, Tosi, D, Armas, M, Ruocco, V, Ayala, F, Balato, N, Gaudiello, F, Cimmino, Gf, Monfrecola, G, Gallo, L, Argenziano, G, Fulgione, E, Berruti, G, Ceparano, I, De Michele, I, Giorgiano, D, Leigheb, G, Deledda, S, Peserico, A, Alaibac, M, Piaserico, S, Schiesari, L, Dan, G, Mattei, I, Oro, E, Aricò, M, Bongiorno, Mr, Angileri, R, Amato, S, Todaro, F, Milioto, M, Bellastro, R, Di Nuzzo, S, De Panfilis, G, Zanni, M, Borroni, G, Cananzi, R, Brazzelli, V, Lisi, P, Stingeni, L, Hansel, K, Pierfelice, V, Donelli, S, Rastelli, D, Gasperini, M, Barachini, P, Cecchi, R, Bartoli, L, Pavesi, M, De Paola, S, Corradin, Mt, Ricciuti, F, Piccirillo, A, Viola, L, Tataranni, M, Mautone, Mg, Lo Scocco, G, Niccoli, Mc, Brunasso Vernetti AM, Gaddoni, G, Resta, F, Casadio, Mc, Arcidiaco, Mc, Luvarà, Mc, Albertini, G, Di Lernia, V, Guareschi, E, Catrani, S, Morri, M, De Simone, C, D'Agostino, M, Agostino, I, Calvieri, S, Cantoresi, F, Richetta, A, Sorgi, P, Carnevale, C, Nicolucci, F, Berardesca, E, Gubinelli, E, Chimenti, S, Talamonti, M, Camplone, G, Cruciani, G, Riccardi, F, Barbati, R, Zumiani, G, Pagani, W, Malagoli, Pg, Pellicano, R, Donadio, D, Di Vito, C, Cottoni, F, Montesu, Ma, Pirodda, C, Addis, G, Marongiu, P, Farris, A, Cacciapuoti, M, Verrini, A, Desirello, G, Gnone, M, Fimiani, M, Pellegrino, M, Castelli, G, Zappalà, L, Sesana, G, Ingordo, V, Vozza, Dg, Di Giuseppe, D, Fasciocco, D, Nespoli, P, Papini, M, Cicoletti, M, Bernengo, Mg, Ortoncelli, M, Bonvicino, A, Capella, G, Doveil, Gc, Forte, M, Peroni, A, Salomone, B, Savoia, P, Pippione, M, Zichichi, L, Frazzitta, M, De Luca, G, Tasin, L, Simonetto, S, Ros, S, Trevisan, G, Patamia, M, Miertusova, S, Patrone, A, Frattasio, A, Piccirillo, F, La Spina, S, Di Gaetano, L, Udine, Marzocchi, V, Motolese, A, Venturi, C, Gai, F, Pasquinucci, S, Bellazzi, Rm, Silvestri, T, Girolomoni, G, Gisondi, P, Veller Fornasa, C, Trevisan, Gp., Gisondi, P, Cazzaniga, S, Chimenti, S, Giannetti, A, Maccarone, M, Picardo, M, Girolomoni, G, Naldi, L, Monfrecola, Giuseppe, Psocare Study, G. r. o. u. p., P., Gisondi, S., Cazzaniga, S., Chimenti, A., Giannetti, M., Maccarone, M., Picardo, G., Girolimoni, L., Naldi, Trevisan, Giusto, Psocare Study Group: [.., M. Reggiani, A. Lanzoni, A. Patrizi, F. Bardazzi, A. Antonucci, S. De Tommaso, R. Balestri, and ]

Subjects
Adult, Male, arterial hypertension, Adolescent, Antineoplastic Agents, Risk Assessment, Severity of Illness Index, Antibodies, Drug Administration Schedule, Cohort Studies, Dose-Response Relationship, Young Adult, Settore MED/35, Age Distribution, Metabolic Diseases, Monoclonal, metabolic disorders, Humans, Psoriasis, Prospective Studies, Registries, Sex Distribution, Antibodies, Monoclonal, Dose-Response Relationship, Drug, Evidence-Based Medicine, Female, Immunosuppressive Agents, Incidence, Italy, Treatment Outcome, 2708, Infectious Diseases, METABOLIC SYNDROME, psoriasis, metabolic abnormalities, Treatment, therapy, Metabolic abnormalitie, metabolic comorbidities, Metabolic abnormalities, Drug
Abstract

OBJECTIVE: To evaluate variations in laboratory parameters and diagnoses of selected clinical conditions up to 16 weeks after starting a new systemic psoriasis treatment for Psocare Registry enrollees. DESIGN: Prospective cohort study. SETTING: Italian public referral centres for psoriasis treatment. PATIENTS: First-time recipients (n = 10,539) of continuous systemic psoriasis treatment for at least 16 weeks. MAIN OUTCOME MEASURE: Mean variations in (weeks 8 and 16) and proportions of patients reaching a clinically meaningful increase in serum levels (week 16) of total and low-density lipoprotein cholesterol, triglycerides, aspartate amino transferase, alanine amino transferase and creatinine, as well as week-16 cumulative incidences of new diagnoses of diabetes mellitus and arterial hypertension. RESULTS: Mean cholesterol and triglyceride levels significantly increased in patients treated with acitretin or cyclosporine. Mean triglyceride levels also increased in efalizumab- and etanercept-treated patients. Mean transaminase values increased in methotrexate-treated patients, and mean aspartate amino transferase levels increased in infliximab-treated patients. The average serum creatinine value increased in cyclosporine-treated patients. Acitretin and cyclosporine were associated with risk of hypercholesterolaemia (odds ratios 1.51 and 1.34) and acitretin with risk of hypertriglyceridaemia (odds ratio 1.43). Methotrexate and infliximab were associated with risk of more than doubling the upper normal aspartate amino transferase (odds ratios 2.06 and 1.87) and alanine amino transferase (odds ratios 2.38 and 1.74) values. The relative risk of developing arterial hypertension and diabetes was increased for patients receiving cyclosporine (odds ratios 3.31 and 2.88). CONCLUSION: Systemic treatments for psoriasis resulted in heterogeneous effects on the parameters analysed.

Published
2013

191. Multicenter experience using total lymphoid irradiation and antithymocyte globulin as conditioning for allografting in hematological malignancies

Author

Messina, G, Giaccone, Luisa, Festuccia, M, Irrera, G, Scortechini, I, Sorasio, R, Gigli, F, Passera, R, Cavattoni, I, Filippi, Andrea Riccardo, Schianca, Fc, Pini, M, Risitano, Am, Selleri, C, Levis, A, Mordini, N, Gallamini, A, Pastano, R, Casini, M, Aglietta, Massimo, Montanari, M, Console, G, Boccadoro, Mario, Ricardi, Umberto, Bruno, Benedetto, and Gruppo Italiano Trapianti di Midollo

Subjects
Male, Myeloid, Transplantation Conditioning, Graft vs Host Disease, total lymphoid irradiation, antithymocyte globulin, bone marrow transplantation, Graft-versus-host disease, Gastroenterology, Severity of Illness Index, HLA Antigens, Recurrence, Nonmyeloablative conditioning, biology, Incidence (epidemiology), Hematopoietic Stem Cell Transplantation, Hematology, Middle Aged, surgical procedures, operative, medicine.anatomical_structure, Hematologic Neoplasms, Histocompatibility, Cyclosporine, Female, Whole-Body Irradiation, Total lymphoid irradiation/antithymocyte globulin, Adult, medicine.medical_specialty, Globulin, anti-thymocyte globulin, Refractory, Antigen, Internal medicine, medicine, Humans, Transplantation, Homologous, hematological malignancies, Aged, Antilymphocyte Serum, Transplantation, business.industry, Mycophenolic Acid, medicine.disease, Survival Analysis, Anti-thymocyte globulin, Surgery, biology.protein, business
Abstract

A non myeloablative conditioning with total lymphoid irradiation (TLI) and antithymocyte globulin (ATG) was shown to protect against graft-versus-host disease (GVHD). To evaluate the effects of TLI-ATG in a multicenter study, 45 heavily pretreated patients, median age 51, with lymphoid (n = 38) and myeloid (n = 7) malignancies were enrolled at 9 centers. Twenty-eight patients (62%) received at least 3 lines of treatment before allografting, and 13 (29%) had refractory/relapsed disease at the time of transplantation. Peripheral blood hematopoietic cells were from HLA identical sibling (n = 30), HLA-matched (n = 9), or 1 antigen HLA-mismatched (n = 6) unrelated donors. A cumulative TLI dose of 8 Gy was administered from day −11 through −1 with ATG at the dose of 1.5 mg/kg/day (from day −11 through −7). GVHD prophylaxis consisted of cyclosporine and mycophenolate mofetil. Donor engraftment was reached in 95% of patients. Grade II to IV acute GVHD (aGVHD) developed in 6 patients (13.3%), and in 2 of these patients, it developed beyond day 100. Incidence of chronic GVHD (cGVHD) was 35.8%. One-year nonrelapse mortality was 9.1%. After a median follow-up of 28 months (range, 3-57 months) from transplantation, median overall survival was not reached, whereas median event-free survival was 20 months. This multicenter experience confirms that TLI-ATG protects against GVHD and maintains graft-vs-tumor effects.

Published
2012

192. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial

Author

Büller, Hr, Gallus, As, Prins, Mh, Raskob, G, Decousus, H, Charbonnier, B, Leizorovicz, A, Laporte, S, Quenet, S, Brandjes, Dp, Middeldorp, S, Blüguermann, J, Amuchastegui, L, Ahuad Guerrero, R, Oberti, P, Alvarez, C, Cassettari, A, Santos, D, Macin, S, Santini, F, Ward, C, Coughlin, P, Salem, H, Gan, E, Leyden, M, Prosser, I, Crispin, P, Carroll, P, Gallus, A, Mcrae, S, Waites, J, Pilger, E, Koppensteiner, R, Kyrle, P, Schinko, H, Mrochek, A, Mitkovskaya, N, Prystrom, A, Motte, S, Ninane, V, Delcroix, M, Hainaut, P, Schneider, E, Saraiva, J, Maia, L, Barreto, S, Fernandes Manenti, E, Araujo, G, Dutra, O, Fiss, E, Moreira, R, Yankov, K, Nenkova, S, Ivanov, Y, Kostov, V, Bhargava, R, Chan, Y, Miron, Mj, Cusson, J, Ugarte, S, Morales, A, Andresen, M, Lanas, F, Arriagada, G, Mendoza, Jj, Zuñiga, C, Sepulveda, P, Wang, C, Liu, Z, Yuan, Y, Ma, Z, Fang, B, Liu, J, Bai, C, Wu, H, Yang, L, Ying, K, Kang, J, Li, Q, Cheng, Z, Zhang, J, Wang, H, Xie, C, Xia, G, Du, Y, Wu, Q, Zhou, X, Chen, L, Yi, Q, Wu, C, Hao, Q, Liu, S, Xiong, S, Jiang, S, Zhao, L, Xiao, Q, Qin, Z, Zhou, J, Dennis, R, Miserque, N, Igueredo, M, Londoño, D, Hildebrando, J, Granados, M, Buitrago, R, Solano, Mh, Pacheco Alvis PM, Botero, R, Saenz, O, Bergovec, M, Padovan, M, Vucic, N, Samarzija, M, Chlumsky, J, Spacek, R, Klimsa, Z, Gregor, P, Povolny, J, Podpera, I, Holm, F, Lang, P, Matoska, P, Sabl, P, Spinar, J, Spac, J, Husted, S, Avnstrom, S, Rasmussen, S, Christensen, A, Guindy, R, Hassanein, M, Paumets, M, Meriste, S, Ferrari, E, Achkar, A, Azarian, R, Meneveau, N, Lorut, C, Mouallem, J, Crestani, B, Proton, A, Salmeron, S, Lerousseau, L, Mottier, D, Wahl, D, Siafakas, N, Papadimitriou, D, Katis, K, Katsaris, G, Gaga, A, Damianos, A, Tipparaju, S, Kalkunte, S, Vidhut, J, Kalashetti, S, Mehta, P, Talwar, D, Ramanathan, R, Mishra, R, Zeltzer, D, Lahav, M, Brenner, B, Caraco, Y, Elias, M, Piovella, F, Barone, M, Poggio, R, Palla, A, Ghirarduzzi, A, Pini, M, Lodigiani, C, Prandoni, Paolo, Agnelli, G, Imberti, D, Scannapieco, G, Salvi, A, Bautista, E, Diaz, J, Mercado, R, Ranero, A, Rodriguez, D, Jerjes, C, Villeda Espinoza, E, Van Der Meer, J, Ijfering, W, Van Marwijk Kooy, M, Boersma, W, Van Leendert, R, Kroon, C, Dullemond Westland, A, Viergever, P, Kuipers, A, Grootenboers, M, Creemers, J, Pieters, W, De Munck, D, Timmer, H, Jackson, S, Sandset, P, Meyer, P, Kristiansen, T, Portugal, J, Paz, E, Salazar, D, Chavez, W, Castillo, L, De Guia, T, Lenora, F, Tomkowski, W, Kloczko, J, Rybak, Z, Gaciong, Z, Sobkowicz, B, Pruszczyk, P, Nizankowski, R, Mirek Bryniarska, E, Kukla, P, Reis, A, França, A, Cortez, M, Sa, J, Santos, F, Marques, Ma, Gordeev, I, Gendlin, G, Yablonsky, P, Sokurenko, G, Soroka, V, Lusov, V, Markov, V, Shvats, Y, Katerlnitskiy, I, Lapin, O, Lyamina, N, Subbotin, Y, Kim, I, Zilber, E, Kchaisheva, L, Poliacik, P, Macek, V, Pretorius, Jp, Abdullah, I, Basson, M, Bollinger, C, Breedt, J, Gani, M, Jansen, J, Le Roux, G, Nortje, H, Van Der Linder, M, Van Zyl, L, Viljoen, J, Bruning, A, Pujol Farriols, R, Raguer, E, Nuffal, D, Sanchez Rodriguez, A, Eriksson, H, Almgren, T, Carlsson, A, Elf, J, Olsson, Cg, Aagesen, J, Savas, I, Sahin, A, Erdogan, Y, Ozhan, M, Ongen, G, Celikel, T, Turker, H, Arseven, O, Tuncay, E, Ozacar, R, Gudz, I, Nykonenko, O, Skupyy, O, Kovalskyy, I, Prasol, V, Cohen, A, Rodriguez Cintron, W, Gurka, D, Bradley, J, Oliver, G, Spyropoulos, A, Lerner, R, Fulmer, J, Lu, Np, Wright, P, Han, D, Servi, R, Nadar, V, Quaranta, A, Gehring, J, Ginsberg, R, Jacobson, A, Colan, D, Vanway, C, Gurza, E, Braslow, B, Shorr, A, Rehm, J, Martin, J, Sellers, M, Concha, M, Gordon, I, Pullman, J, Moran, J, Welker, J, Panzarella, P, Mullins, M, Willms, D, Mcgrew, F, Turki, M, Menajovsky, L., Epidemiologie, MUMC+: KIO Kemta (9), RS: CAPHRI School for Public Health and Primary Care, Amsterdam Cardiovascular Sciences, Vascular Medicine, Department of Vascular Medicine (DVM - AMC), Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA)-University of Amsterdam [Amsterdam] (UvA), SA Pathology at Flinders Medical Center (ASG), Flinders University, Department of Epidemiology (MHP), Maastricht University [Maastricht], College of Public Health (CPH), University of Oklahoma (OU), Centre d'Investigation Clinique (CIC - Brest), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), and Université de Brest (UBO)-Université de Brest (UBO)

Subjects
Male, MESH: Pulmonary Embolism, Oligosaccharides, MESH: Factor X, 030204 cardiovascular system & hematology, MESH: Intention to Treat Analysis, MESH: Aged, 80 and over, 0302 clinical medicine, MESH: Double-Blind Method, 030212 general & internal medicine, MESH: Warfarin, Aged, 80 and over, MESH: Aged, education.field_of_study, Idrabiotaparinux, MESH: Middle Aged, General Medicine, Heparin, Middle Aged, Intention to Treat Analysis, 3. Good health, Pulmonary embolism, Acute Disease, MESH: Acute Disease, Drug Therapy, Combination, Female, medicine.drug, Adult, medicine.medical_specialty, MESH: Enoxaparin, Adolescent, Population, Biotin, MESH: Anticoagulants, Double blind, 03 medical and health sciences, Double-Blind Method, Internal medicine, MESH: Biotin, medicine, Humans, Enoxaparin, education, Aged, MESH: Adolescent, MESH: Humans, Intention-to-treat analysis, business.industry, Warfarin, Anticoagulants, MESH: Adult, Odds ratio, medicine.disease, MESH: Male, Surgery, MESH: Drug Therapy, Combination, Factor X, Pulmonary Embolism, business, MESH: Female, MESH: Oligosaccharides, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; BACKGROUND: Treatment of pulmonary embolism with low-molecular-weight heparin and vitamin K antagonists, such as warfarin, is not ideal. We aimed to assess non-inferiority of idrabiotaparinux, a reversible longlasting indirect inhibitor of activated factor X, to warfarin in patients with acute symptomatic pulmonary embolism. METHODS: In our randomised, double-blind, double-dummy, non-inferiority trial, we enrolled adults with objectively documented acute symptomatic pulmonary embolism attending 291 centres in 37 countries. We excluded patients who were pregnant, had active bleeding, kidney failure, or malignant hypertension, or were at high risk of death, bleeding, or adverse reactions to study drugs. We randomly allocated patients to receive 5-10 days' enoxaparin 1*0 mg/kg twice daily followed by subcutaneous idrabiotaparinux (starting dose 3*0 mg) or adjusted-dose warfarin (target international normalised ratio 2*0-3*0); regimens lasted 3 months or 6 months dependent on clinical presentation. Block randomisation was done with a central interactive computerised system, stratified by study centre and intended treatment duration. The primary efficacy outcome was recurrent venous thromboembolism at 99 days after randomisation. We estimated the odds ratio and 95% CI with a Mantel-Haenzsel χ(2) analysis (non-inferiority margin 2*0) in the intention-to-treat population. The main safety outcome was clinically relevant bleeding (major or non-major) in all patients at day 99. This study is registered with ClinicalTrials.gov, number NCT00345618. FINDINGS: Between Aug 1, 2006, and Jan 31, 2010, we enrolled 3202 patients aged 18-96 years. 34 (2%) of 1599 patients randomly allocated to receive enoxaparin-idrabiotaparinux and 43 (3%) of 1603 patients randomly allocated to receive enoxaparin-warfarin had recurrent venous thromboembolism (odds ratio 0*79, 95% CI 0*50-1*25; p(non-inferiority)=0*0001). 72 (5%) of 1599 patients in the enoxaparin-idrabiotaparinux group and 106 (7%) of 1603 patients in the enoxaparin-warfarin group had clinically relevant bleeding (0*67, 0*49-0*91; p(superiority)=0*0098). We noted similar differences in outcomes in those patients treated to 6 months. INTERPRETATION: Idrabiotaparinux could provide an attractive alternative to warfarin for the long-term treatment of pulmonary embolism, and seems to be associated with reduced bleeding. FUNDING: Sanofi-Aventis (Paris, France).

Published
2012
Full Text
View/download PDF

194. Pigmentary traits, modalities of sun reaction, history of sunburns, and melanocytic nevi as risk factors for cutaneous malignant melanoma in the italian population: Results of a collaborative case-control study

Author

Naldi L, Imberti GL, Parazzini F, Gallus S, La Vecchia C, Cainelli T, Rebora A, Tognoni G, Peserico A, Arcangeli F, Calista D, Landi G, Di Landro A, Puiatti P, Catricalà C, Eibenschutz L, Gallicano RS, Lo Scocco G, Di Lernia V, Tosti A, Misciali C, Scardigli F, Cristofolini M, Simonacci M, Sigona M, Pasolini G, Manganoni A, Lonati A, Betti R, Barba A, De Agostini F, Chieregato C, Bertazzoni MG, Danese P, Stanganelli I, Moretti S, Carli YP, Iannantuono M, Taddeucci P, Virgili A, Fenizi G, Rossi E, Pini M, Galbiati G, Locatelli A., FABBROCINI, GABRIELLA, BALATO, NICOLA, SANTOIANNI, PIETRO, Naldi, L, Imberti, Gl, Parazzini, F, Gallus, S, La Vecchia, C, Cainelli, T, Rebora, A, Tognoni, G, Peserico, A, Arcangeli, F, Calista, D, Landi, G, Di Landro, A, Puiatti, P, Catricalà, C, Eibenschutz, L, Gallicano, R, Lo Scocco, G, Di Lernia, V, Tosti, A, Misciali, C, Scardigli, F, Cristofolini, M, Simonacci, M, Sigona, M, Pasolini, G, Manganoni, A, Lonati, A, Betti, R, Barba, A, De Agostini, F, Chieregato, C, Fabbrocini, Gabriella, Balato, Nicola, Santoianni, Pietro, Bertazzoni, Mg, Danese, P, Stanganelli, I, Moretti, S, Carli, Yp, Iannantuono, M, Taddeucci, P, Virgili, A, Fenizi, G, Rossi, E, Pini, M, Galbiati, G, and Locatelli, A.

Subjects
Melanocytic nevi, Pigmentary trait, Case-control study, Risk factor, Cutaneous malignant melanoma, Sunburns, Mediterranean population
Abstract

BACKGROUND. To the authors' knowledge, limited data are available from Mediterranean populations concerning risk factors for malignant melanoma. A few Italian case-control studies have produced conflicting results regarding the association between malignant melanoma and pigmentary traits, sunburns, and melanocytic nevi. METHODS. A case-control study was conducted within the framework of the Italian Group for Epidemiologic Research in Dermatology (GISED). Twenty-seven centers in the north and south of Italy participated. A total of 542 cases and 538 controls were entered onto the study. A standardized questionnaire was administered to cases and controls. Cases and controls also were examined by trained dermatologists who were required to count the number of melanocytic nevi (those measuring ≥ 2 mm and > 6 mm in greatest dimension, separately) and to make judgments regarding pigmentary traits. RESULTS. In the multivariate analysis, eye and skin color, propensity to sunburn, history of sunburns before age 15 years, and solar lentigines all were associated with malignant melanoma. In addition, the risk of melanoma increased with the number of melanocytic nevi ≥ 2 mm. Nevi > 6 mm in greatest dimension had effects on risk that appeared to be independent from the effects of smaller nevi (2-6 mm). CONCLUSIONS. The results of the current study largely are similar to those obtained in northern European countries, the U.S., and Australia and provide further evidence of the importance of selected pigmentary traits, sun exposure, and the number of melanocytic nevi in the risk of cutaneous malignant melanoma. (C) 2000 American Cancer Society.

Published
2000

197. RIC vs. MAC followed by allogeneic stem cell transplantation for patients with MDS or secondary AML: A prospective, randomized phase III study of the CMWP of the EBMT (RICMAC-Trial)

Author

Kroeger, N., Brand, R., Niederwieser, D., Platzbecker, U., Huebel, K., Weber, T., Robin, M., Stelljes, M., Afanasiev, B., Heim, D., Deliliers, G. Lambertenghi, Onida, F., Dreger, P., Pini, M., Guidi, S., Volin, L., Gramatzki, M., Bethge, W., Poire, X., Kobbe, G., van Os, M., Iacobelli, S., de Witte, T., Kroeger, N., Brand, R., Niederwieser, D., Platzbecker, U., Huebel, K., Weber, T., Robin, M., Stelljes, M., Afanasiev, B., Heim, D., Deliliers, G. Lambertenghi, Onida, F., Dreger, P., Pini, M., Guidi, S., Volin, L., Gramatzki, M., Bethge, W., Poire, X., Kobbe, G., van Os, M., Iacobelli, S., and de Witte, T.

Published
2015

198. Fluid dynamic design and analysis of a highly loaded Centrifugal rotor for mini orc power systems

Author

Vitale, S. (author), Pini, M. (author), Ghidoni, A. (author), Colonna di Paliano, P. (author), Vitale, S. (author), Pini, M. (author), Ghidoni, A. (author), and Colonna di Paliano, P. (author)

Abstract

Organic Rankine Cycle (ORC) power systems are a well-established technology for the conversion of thermal energy sources in the small-to-medium power range. In the last few years, efforts have been devoted to the development of mini ORC (mORC) power systems (5- 30 kWe) for waste heat recovery from truck engines, or distributed conversion of concentrated solar radiation. In these high-temperature applications the expander is arguably the most critical component. Due to the high expansion ratio, turbo-expanders are typically preferred. Recently, a multi-stage radial-outflow turbine (ROT) configuration for ORC power systems has been studied. However, even if the authors preliminarily demonstrated that ROT may allow for compact and efficient expanders [1], some research questions are still open. Notably, the key point is the fluid dynamic design of the first stages, which are subject to severe flow conditions (very high flow deflection, low aspect ratio of the blades and with high tip clearance losses). This work thus proposes a novel design methodology for centrifugal cascades, specifically targeted to the first rotor of the mORC centrifugal turbine described in Ref. [1]. Blades are initially designed using a novel in-house Turbomachinery Blade Modeler (BM), then performance is verified by means of 3D CFD simulation on unstructured grids using the solver SU2, recently extended also in-house to treat non ideal compressible fluid flows [2]. Results show that traditional blade design rules for axial cascades are not directly extendable to centrifugal profiles and new design guidelines are needed. Moreover, the 3D performance of the cascade has also been investigated by taking into account tip clearance and secondary loss mechanisms. Finally, an accurate comparison with the mean-line code predictions is provided. As expected, the outcome of the study reveals moderate discrepancy between the CFD results and the mean-line code. This suggests that in case of non-conventional, Aerodynamics, Wind Energy & Propulsion, Aerospace Engineering

Published
2015

199. Differences among young adults, adults and elderly chronic myeloid leukemia patients

Author

Castagnetti, F, Gugliotta, G, Baccarani, M, Breccia, M, Specchia, G, Levato, L, Abruzzese, E, Rossi, G, Iurlo, A, Martino, B, Pregno, P, Stagno, F, Cuneo, A, Bonifacio, M, Gobbi, M, Russo, D, Gozzini, A, Tiribelli, M, De Vivo, A, Alimena, G, Cavo, M, Martinelli, G, Pane, F, Saglio, G, Rosti, G, Salvi, F, Pini, M, Leoni, P, Rupoli, S, Galieni, P, Bigazzi, C, Cantore, N, Palmieri, F, Albano, F, Russo Rossi, A, Rambaldi, A, Intermesoli, T, Palandri, F, Testoni, N, Luatti, S, Soverini, S, Iacobucci, I, Bochicchio, M, Apolinari, M, Fogli, M, Cervello, I, Capucci, A, Malagola, M, Malpignano, A, Girasoli, M, Angelucci, E, Usala, E, Storti, S, De Biasi, E, Tagariello, G, Sartori, R, Di Raimondo, F, Vigneri, P, Impera, S, Molica, S, Lanza, F, Viganò, C, Grasso, M, Rapezzi, D, Cavazzini, F, Bosi, A, Santini, V, Capalbo, S, Spinosa, G, Pierri, I, Bergamaschi, M, Carella, A, Bacigalupo, A, De Blasio, A, Ciccone, F, Di Renzo, N, Musolino, C, Russo, S, Cortelezzi, A, Morra, E, Pungolino, E, Luppi, M, Marasca, R, Pogliani, E, GAMBACORTI PASSERINI, C, Luciano, L, Ferrara, F, Annunziata, M, Latte, G, Noli, D, Rege Cambrin, G, Fava, C, Semenzato, G, Binotto, G, Fabbiano, F, Turri, D, Siragusa, S, Caracciolo, C, Musso, M, Porretto, F, Aversa, F, Crugnola, M, Cazzola, M, Orlandi, E, Falini, B, Falzetti, F, Visani, G, Isidori, A, Fioritoni, G, Di Lorenzo, R, Vallisa, D, Trabacchi, E, Petrini, M, Galimberti, S, Pizzuti, M, Zaccaria, A, Salvucci, M, Ronco, F, Ielo, D, Merli, F, Avanzini, P, Tosi, P, Merli, A, Musto, P, De Stefano, V, Sica, S, Latagliata, R, De Fabritiis, P, Trawiska, M, Majolino, I, Pacilli, L, Ronci, B, Cedrone, M, Petti, M, Pisani, F, Tafuri, A, Montefusco, E, Iuliano, F, Dore, F, Pardini, S, Bocchia, M, Defina, M, Liberati, A, Luzzi, D, Boccadoro, M, Ferrero, D, Vitolo, U, Gherlinzoni, F, Calistri, E, Fanin, R, Pizzolo, G, Meneghini, V, Rodighiero, F, D'Emilio, A, GAMBACORTI PASSERINI, CARLO, D'Emilio, A., Castagnetti, F, Gugliotta, G, Baccarani, M, Breccia, M, Specchia, G, Levato, L, Abruzzese, E, Rossi, G, Iurlo, A, Martino, B, Pregno, P, Stagno, F, Cuneo, A, Bonifacio, M, Gobbi, M, Russo, D, Gozzini, A, Tiribelli, M, De Vivo, A, Alimena, G, Cavo, M, Martinelli, G, Pane, F, Saglio, G, Rosti, G, Salvi, F, Pini, M, Leoni, P, Rupoli, S, Galieni, P, Bigazzi, C, Cantore, N, Palmieri, F, Albano, F, Russo Rossi, A, Rambaldi, A, Intermesoli, T, Palandri, F, Testoni, N, Luatti, S, Soverini, S, Iacobucci, I, Bochicchio, M, Apolinari, M, Fogli, M, Cervello, I, Capucci, A, Malagola, M, Malpignano, A, Girasoli, M, Angelucci, E, Usala, E, Storti, S, De Biasi, E, Tagariello, G, Sartori, R, Di Raimondo, F, Vigneri, P, Impera, S, Molica, S, Lanza, F, Viganò, C, Grasso, M, Rapezzi, D, Cavazzini, F, Bosi, A, Santini, V, Capalbo, S, Spinosa, G, Pierri, I, Bergamaschi, M, Carella, A, Bacigalupo, A, De Blasio, A, Ciccone, F, Di Renzo, N, Musolino, C, Russo, S, Cortelezzi, A, Morra, E, Pungolino, E, Luppi, M, Marasca, R, Pogliani, E, GAMBACORTI PASSERINI, C, Luciano, L, Ferrara, F, Annunziata, M, Latte, G, Noli, D, Rege Cambrin, G, Fava, C, Semenzato, G, Binotto, G, Fabbiano, F, Turri, D, Siragusa, S, Caracciolo, C, Musso, M, Porretto, F, Aversa, F, Crugnola, M, Cazzola, M, Orlandi, E, Falini, B, Falzetti, F, Visani, G, Isidori, A, Fioritoni, G, Di Lorenzo, R, Vallisa, D, Trabacchi, E, Petrini, M, Galimberti, S, Pizzuti, M, Zaccaria, A, Salvucci, M, Ronco, F, Ielo, D, Merli, F, Avanzini, P, Tosi, P, Merli, A, Musto, P, De Stefano, V, Sica, S, Latagliata, R, De Fabritiis, P, Trawiska, M, Majolino, I, Pacilli, L, Ronci, B, Cedrone, M, Petti, M, Pisani, F, Tafuri, A, Montefusco, E, Iuliano, F, Dore, F, Pardini, S, Bocchia, M, Defina, M, Liberati, A, Luzzi, D, Boccadoro, M, Ferrero, D, Vitolo, U, Gherlinzoni, F, Calistri, E, Fanin, R, Pizzolo, G, Meneghini, V, Rodighiero, F, D'Emilio, A, GAMBACORTI PASSERINI, CARLO, and D'Emilio, A.

Abstract

Background: The incidence of chronic myeloid leukemia (CML) increases with age, but it is unclear how the characteristics of the disease vary with age. In children, where CML is very rare, it presents with more aggressive features, including huge splenomegaly, higher cell count and higher blast cell percentage. Patients and methods: To investigate if after childhood the disease maintains or loses these characteristics of aggressiveness, we analyzed 2784 adult patients, at least 18 years old, registered by GIMEMA CMLWP over a 40-year period. Results: Young adults (YAs: 18-29 years old) significantly differed from adults (30-59 years old) and elderly patients (at least 60 years old) particularly for the frequency of splenomegaly (71%, 63% and 55%, P < 0.001), and the greater spleen size (median value: 4.5, 3.0 and 1.0 cm, P < 0.001). According to the EUTOS score, that is age-independent, high-risk patients were more frequent among YAs, than among adult and elderly patients (18%, 9% and 6%, P < 0.001). In tyrosine kinase inhibitors-treated patients, the rates of complete cytogenetic and major molecular response were lower in YAs, and the probability of transformation was higher (16%, 5% and 7%, P = 0.011). Conclusions: The characteristics of CML or the host response to leukemia differ with age. The knowledge of these differences and of their causes may help to refine the treatment and to improve the outcome.

Published
2015

200. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial

Author

Rambaldi, A, Grassi, A, Masciulli, A, Boschini, C, Micò, Mc, Busca, A, Bruno, B, Cavattoni, I, Santarone, S, Raimondi, R, Montanari, M, Milone, G, Chiusolo, Patrizia, Pastore, D, Guidi, S, Patriarca, F, Risitano, Am, Saporiti, G, Pini, M, Terruzzi, E, Arcese, W, Marotta, G, Carella, Am, Nagler, A, Russo, D, Corradini, P, Alessandrino, Ep, Torelli, Gf, Scimè, R, Mordini, N, Oldani, E, Marfisi, Rm, Bacigalupo, A, Bosi, A., Chiusolo, Patrizia (ORCID:0000-0002-1355-1587), Rambaldi, A, Grassi, A, Masciulli, A, Boschini, C, Micò, Mc, Busca, A, Bruno, B, Cavattoni, I, Santarone, S, Raimondi, R, Montanari, M, Milone, G, Chiusolo, Patrizia, Pastore, D, Guidi, S, Patriarca, F, Risitano, Am, Saporiti, G, Pini, M, Terruzzi, E, Arcese, W, Marotta, G, Carella, Am, Nagler, A, Russo, D, Corradini, P, Alessandrino, Ep, Torelli, Gf, Scimè, R, Mordini, N, Oldani, E, Marfisi, Rm, Bacigalupo, A, Bosi, A., and Chiusolo, Patrizia (ORCID:0000-0002-1355-1587)

Abstract

BACKGROUND: The standard busulfan-cyclophosphamide myeloablative conditioning regimen is associated with substantial non-relapse mortality in patients older than 40 years with acute myeloid leukaemia who are undergoing allogeneic stem-cell transplantation. Because the combination of busulfan plus fludarabine has been proposed to reduce non-relapse mortality, we aimed to compare this treatment with busulfan plus cyclophosphamide as a preparative regimen in these patients. METHODS: We did an open-label, multicentre, randomised, phase 3 trial for patients with acute myeloid leukaemia at 25 hospital transplant centres in Italy and one in Israel. Eligible patients were aged 40-65 years, had an Eastern Cooperative Oncology Group performance status less than 3, and were in complete remission. Patients were randomly assigned 1:1 to receive intravenous busulfan plus cyclophosphamide or busulfan plus fludarabine. Treatment allocations were not masked to investigators or patients. Randomisation was done centrally via a dedicated web-based system using remote data entry, with patients stratified by donor type and complete remission status. Patients allocated to busulfan plus cyclophosphamide received intravenous busulfan 0·8 mg/kg four times per day during 2 h infusions for four consecutive days (16 doses from days -9 through -6; total dose 12·8 mg/kg) and cyclophosphamide at 60 mg/kg per day for two consecutive days (on days -4 and -3; total dose 120 mg/kg). Patients allocated to busulfan plus fludarabine received the same dose of intravenous busulfan (from days -6 through -3) and fludarabine at 40 mg/m(2) per day for four consecutive days (from days -6 through -3; total dose 160 mg/m(2)). The primary endpoint was 1-year non-relapse mortality, which was assessed on an intention-to-treat basis; safety outcomes were assessed in the per-protocol population. This trial has been completed and is registered with ClinicalTrials.gov, number NCT01191957. FINDINGS: Between Jan 3, 2008

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results